Hims & Hers Health Inc. Aktie News

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. Labs measures key markers over time and provides doctor-developed action plans that can power real shifts in health outcomes. With this new, pr...

The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.

The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.

These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.

We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'...

Hims & Hers continues to generate strong revenue growth. The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform.

Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-home cancer screening, and is in renewed talks with Novo Nordisk for oral Wegovy distribution. Management guides for robust 4Q25 and full-year 2025 revenue and EBITDA, with international expansion an...